
There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.

There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.

Shaji Kumar, professor of medicine, Division of Hematology, Mayo Clinic, discusses common treatment-related adverse events from monoclonal antibodies in patients with multiple myeloma.

Published: September 23rd 2015 | Updated:

Published: September 23rd 2015 | Updated: